Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and clinical importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.

International Collaborative Study to Assess Cardiovascular Risk and Evaluate Long-term Health in Cats with Pre-clinical Hypertrophic Cardiomyopathy and Apparently Healthy Cats : The REVEAL Study / P. Fox, B. Keene, K. Lamb, K. Schober, V. Chetboul, V. Luis Fuentes, G. Wess, J. Payne, D. Hogan, A. Motsinger-Reif, J. Häggström, E. Trehiou-Sechi, D. Fine-Ferreira, R. Nakamura, P. Lee, M. Singh, W. Ware, J. Abbott, G. Culshaw, S. Riesen, M. Borgarelli, M. Lesser, N. Van Israel, E. Cote, J. Rush, B. Bulmer, R. Santilli, A. Vollmar, M. Bossbaly, N. Quick, C. Bussadori, J. Bright, A. Estrada, D. Ohad, M.J. Fernández del Palacio, J. Lunney Brayley, D. Schwartz, C. Bove, S. Gordon, S. Jung, P. Brambilla, N.S. Moise, C. Stauthammer, R. Stepien, C. Quintavalla, C. Amberger, F. Manczur, Y. Hung, R. Lobetti, M. De Swarte, A. Tamborini, C. Mooney, M. Oyama, A. Komolov, Y. Fujii, R. Pariaut, M. Uechi, V.Y. Tachika Ohara. - In: JOURNAL OF VETERINARY INTERNAL MEDICINE. - ISSN 1939-1676. - 32:3(2018), pp. 930-943. [10.1111/jvim.15122]

International Collaborative Study to Assess Cardiovascular Risk and Evaluate Long-term Health in Cats with Pre-clinical Hypertrophic Cardiomyopathy and Apparently Healthy Cats : The REVEAL Study

P. Brambilla
Membro del Collaboration Group
;
2018

Abstract

Background: Hypertrophic cardiomyopathy is the most prevalent heart disorder in cats and principal cause of cardiovascular morbidity and mortality. Yet, the impact of preclinical disease is unresolved. Hypothesis/objectives: Observational study to characterize cardiovascular morbidity and survival in cats with preclinical nonobstructive (HCM) and obstructive (HOCM) hypertrophic cardiomyopathy and in apparently healthy cats (AH). Animals: One thousand seven hundred and thirty client-owned cats (430 preclinical HCM; 578 preclinical HOCM; 722 AH). Methods: Retrospective multicenter, longitudinal, cohort study. Cats from 21 countries were followed through medical record review and owner or referring veterinarian interviews. Data were analyzed to compare long-term outcomes, incidence, and risk for congestive heart failure (CHF), arterial thromboembolism (ATE), and cardiovascular death. Results: During the study period, CHF, ATE, or both occurred in 30.5% and cardiovascular death in 27.9% of 1008 HCM/HOCM cats. Risk assessed at 1, 5, and 10 years after study entry was 7.0%/3.5%, 19.9%/9.7%, and 23.9%/11.3% for CHF/ATE, and 6.7%, 22.8%, and 28.3% for cardiovascular death, respectively. There were no statistically significant differences between HOCM compared with HCM for cardiovascular morbidity or mortality, time from diagnosis to development of morbidity, or cardiovascular survival. Cats that developed cardiovascular morbidity had short survival (mean ± standard deviation, 1.3 ± 1.7 years). Overall, prolonged longevity was recorded in a minority of preclinical HCM/HOCM cats with 10% reaching 9-15 years. Conclusions and clinical importance: Preclinical HCM/HOCM is a global health problem of cats that carries substantial risk for CHF, ATE, and cardiovascular death. This finding underscores the need to identify therapies and monitoring strategies that decrease morbidity and mortality.
arterial thromboembolism; asymptomatic; congestive heart failure; epidemiology; incidence; outcome; survival
Settore VET/08 - Clinica Medica Veterinaria
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
2018 REVEAL study.pdf

accesso aperto

Descrizione: Standard Article
Tipologia: Publisher's version/PDF
Dimensione 2.15 MB
Formato Adobe PDF
2.15 MB Adobe PDF Visualizza/Apri
Veterinary Internal Medicne - 2018 - - International collaborative study to assess cardiovascular risk and evaluate.pdf

accesso aperto

Descrizione: Erratum
Tipologia: Publisher's version/PDF
Dimensione 197.11 kB
Formato Adobe PDF
197.11 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1009612
Citazioni
  • ???jsp.display-item.citation.pmc??? 45
  • Scopus 90
  • ???jsp.display-item.citation.isi??? 87
social impact